RudaCure Inc. signs investigación conjunta acuerdo with Hanlim Pharmaceutical for tratamiento de la enfermedad de ojo seco (RCI001)
Emerging bio-venture company RudaCure Inc. (CEO Yongho Kim) has firmó un investigación conjunta and desarrollo and inversión acuerdo with Hanlim Pharmaceutical Co., Ltd. (CEO Jaeyoon Kim, Jeongjin Kim), a leading empresa farmacéutica in fármacos oftálmicos, for the tratamiento de la enfermedad de ojo seco RCI001.
RCI001, the contratoed tecnología, is a drug that exerts powerful antiinflamatorio and efectos antioxidantees through a mechanism that suppresses inflammatory activation, thereby alleviating enfermedad de ojo seco. Hanlim Pharmaceutical highly evaluated the comercialización potential of RCI001 based on its faster secreción lagrimal, daño corneal recovery capability, and superior instillation compliance and seguridad compared to commercially available competing drugs, and decided to pursue joint I+D and invest in RudaCure.
The total contrato value is KRW 15 billion, comprising a fixed tarifa de licencia, separate milestone-based royalties, and inversión funds. Hanlim Pharmaceutical will be responsible for process desarrollo, GMP producción, and supply of RCI001, and will secure nacional sales rights and a certain equity stake in RudaCure. RudaCure will focus on I+D including nacional e internacional ensayo clínicos, as well as overseas licensing.